These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 26310188)

  • 21. Comparative pharmacokinetics of factor VIII and recombinant factor IX: for which coagulation factors should half-life change with age?
    Björkman S
    Haemophilia; 2013 Nov; 19(6):882-6. PubMed ID: 24165155
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factor Activity Assays for Monitoring Extended Half-Life FVIII and Factor IX Replacement Therapies.
    Kitchen S; Tiefenbacher S; Gosselin R
    Semin Thromb Hemost; 2017 Apr; 43(3):331-337. PubMed ID: 28264199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical pattern of hemophilia and causes of variability.
    Mingot-Castellano ME
    Blood Coagul Fibrinolysis; 2019 Sep; 30(1S Suppl 1):S4-S6. PubMed ID: 31517708
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention and Management of Bleeding Episodes in Children with Hemophilia.
    Ljung RCR
    Paediatr Drugs; 2018 Oct; 20(5):455-464. PubMed ID: 30128815
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current management of hemophilia B: recommendations, complications and emerging issues.
    Franchini M
    Expert Rev Hematol; 2014 Oct; 7(5):573-81. PubMed ID: 25112898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New therapies for hemophilia.
    Pipe SW
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):650-656. PubMed ID: 27913542
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monitoring of modified factor VIII and IX products.
    Kitchen S; Gray E; Mertens K
    Haemophilia; 2014 May; 20 Suppl 4():36-42. PubMed ID: 24762273
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The reversal of inhibitors in congenital hemophilia.
    DeFrates SR; McDonagh KT; Adams VR
    Pharmacotherapy; 2013 Feb; 33(2):157-64. PubMed ID: 23355059
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical evaluation of factors VIII and IX manufactured in Hungary, based on results of the first half year].
    Nemes L; Ceglédi A; Szabó G; Varga M; Sas G
    Orv Hetil; 1998 Mar; 139(13):749-52. PubMed ID: 9578703
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of long-acting recombinant FVIII and FIX Fc fusion proteins for the management of hemophilia.
    Shapiro A
    Expert Opin Biol Ther; 2013 Sep; 13(9):1287-97. PubMed ID: 23930915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Innovative Pharmacological Therapies for the Hemophilias Not Based on Deficient Factor Replacement.
    Mannucci PM; Mancuso ME; Santagostino E; Franchini M
    Semin Thromb Hemost; 2016 Jul; 42(5):526-32. PubMed ID: 27148843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Extended half-life clotting factor concentrates: results from published clinical trials.
    Young G; Mahlangu JN
    Haemophilia; 2016 Jul; 22 Suppl 5():25-30. PubMed ID: 27405672
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.
    Goldstein B; Geldziler B; Bjerre J; Seremetis S
    Transfus Apher Sci; 2008 Feb; 38(1):25-32. PubMed ID: 18267372
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended Half-Life Factor VIII/Factor IX Products: Assay Discrepancies and Implications for Hemophilia Management.
    Müller J; Goldmann G; Marquardt N; Pötzsch B; Oldenburg J
    Hamostaseologie; 2020 Nov; 40(S 01):S15-S20. PubMed ID: 33187006
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prophylactic Treatment of Children with Hemophilia in Sweden.
    Ljung R
    Semin Thromb Hemost; 2024 Jul; 50(5):714-719. PubMed ID: 38499191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2017 Clinical trials update: Innovations in hemophilia therapy.
    Hartmann J; Croteau SE
    Am J Hematol; 2016 Dec; 91(12):1252-1260. PubMed ID: 27563744
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Importance of pharmacokinetics in the management of hemophilia.
    Barnes C
    Pediatr Blood Cancer; 2013; 60 Suppl 1():S27-9. PubMed ID: 23109436
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The long and short of it: using the new factor products.
    Dunn A
    Hematology Am Soc Hematol Educ Program; 2015; 2015():26-32. PubMed ID: 26637697
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factor concentrate usage in persons with hemophilia in New York State.
    Linden JV; Kolakoski MH; Lima JE; Du P; Lipton RA
    Transfusion; 2003 Apr; 43(4):470-5. PubMed ID: 12662279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Expression and characterization of a novel human recombinant factor IX molecule with enhanced in vitro and in vivo clotting activity.
    Perot E; Enjolras N; Le Quellec S; Indalecio A; Girard J; Negrier C; Dargaud Y
    Thromb Res; 2015 May; 135(5):1017-24. PubMed ID: 25795563
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.